- Sweden
- /
- Healthtech
- /
- OM:PTRK
Physitrack Third Quarter 2024 Earnings: €0.02 loss per share (vs €0.015 loss in 3Q 2023)
Physitrack (STO:PTRK) Third Quarter 2024 Results
Key Financial Results
- Revenue: €3.89m (flat on 3Q 2023).
- Net loss: €376.2k (loss widened by 57% from 3Q 2023).
- €0.02 loss per share (further deteriorated from €0.015 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Physitrack Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden.
Performance of the Swedish Healthcare Services industry.
The company's shares are down 27% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Physitrack you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:PTRK
Physitrack
Provides digital healthcare services in the United Kingdom, Europe, North America, and internationally.
Proven track record with mediocre balance sheet.